UBS Group AG Acquires 215,645 Shares of Niagen Bioscience, Inc. $NAGE

UBS Group AG grew its holdings in shares of Niagen Bioscience, Inc. (NASDAQ:NAGE) by 18.0% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,411,742 shares of the company’s stock after buying an additional 215,645 shares during the period. UBS Group AG owned approximately 1.77% of Niagen Bioscience worth $8,979,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently modified their holdings of NAGE. SG Americas Securities LLC bought a new position in shares of Niagen Bioscience during the 3rd quarter worth approximately $482,000. State of Alaska Department of Revenue bought a new position in shares of Niagen Bioscience during the 3rd quarter worth approximately $44,000. Wealth Enhancement Advisory Services LLC bought a new position in shares of Niagen Bioscience during the 3rd quarter worth approximately $126,000. Strs Ohio bought a new position in shares of Niagen Bioscience during the 3rd quarter worth approximately $391,000. Finally, Hussman Strategic Advisors Inc. bought a new position in shares of Niagen Bioscience in the 3rd quarter worth $980,000. 15.41% of the stock is currently owned by institutional investors.

Niagen Bioscience Stock Performance

NAGE opened at $3.65 on Monday. The company’s fifty day moving average price is $4.60 and its two-hundred day moving average price is $5.67. Niagen Bioscience, Inc. has a 1-year low of $3.60 and a 1-year high of $14.69. The company has a market cap of $290.69 million, a price-to-earnings ratio of 17.38 and a beta of 2.17.

Niagen Bioscience (NASDAQ:NAGE) last released its quarterly earnings data on Wednesday, May 6th. The company reported $0.07 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.01. Niagen Bioscience had a net margin of 14.29% and a return on equity of 22.68%. The firm had revenue of $31.47 million for the quarter. As a group, equities analysts forecast that Niagen Bioscience, Inc. will post 0.22 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on NAGE shares. HC Wainwright cut their target price on Niagen Bioscience from $12.00 to $11.00 and set a “buy” rating on the stock in a report on Monday, May 11th. Wall Street Zen downgraded shares of Niagen Bioscience from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Weiss Ratings restated a “hold (c)” rating on shares of Niagen Bioscience in a report on Tuesday, April 21st. Finally, Canaccord Genuity Group lowered their price objective on shares of Niagen Bioscience from $13.00 to $10.00 and set a “buy” rating on the stock in a report on Tuesday, May 5th. Three research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $14.67.

Niagen Bioscience Profile

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services.